Science synergy draws REAADS to NovaDx:
This article was originally published in Clinica
NovaDx is to buy the privately-owned REAADS Medical Products. NovaDx, which is listed on the Vancouver stock exchange, will issue shares to acquire the US company, which develops diagnostic blood tests for vascular and autoimmune disease, including arthritis. REAADS had sales of $2.5 million in 1996. REAADS' focus on rheumatological disease and NovDx's research into arthritis and osteoporosis led to the merger.